B&L invests in presbyopia

Article

Bausch & Lomb has made an equity investment in AcuFocus.

Bausch & Lomb has made an equity investment in - and secures an exclusive option to purchase - AcuFocus, a privately held company in California, USA.

AcuFocus is developing a corneal inlay, the ACI 7000, for the treatment of presbyopia. The inlay is implanted in the cornea under a LASIK flap and incorporates technology that increases a patient's depth of field, thereby improving near vision. The procedure involves no tissue removal and does not permanently alter the cornea, so pre-implant vision can be restored should the inlay be removed. Terms of the agreement were not disclosed.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.